Spleen Tyrosine Kinase Inhibitor TAK-659 Prevents Splenomegaly and Tumor Development in a Murine Model of Epstein-Barr Virus-Associated Lymphoma
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Spleen Tyrosine Kinase Inhibitor TAK-659 Prevents Splenomegaly and Tumor Development in a Murine Model of Epstein-Barr Virus-Associated Lymphoma
Authors
Keywords
-
Journal
mSphere
Volume 3, Issue 4, Pages -
Publisher
American Society for Microbiology
Online
2018-08-20
DOI
10.1128/mspheredirect.00378-18
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Discovery of TAK-659 an orally available investigational inhibitor of Spleen Tyrosine Kinase (SYK)
- (2016) Betty Lam et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- Inhibition of BCR signaling using the Syk inhibitor TAK-659 prevents stroma-mediated signaling in chronic lymphocytic leukemia cells
- (2016) Noelia Purroy et al. Oncotarget
- An open-label phase 2 trial of entospletinib (GS-9973), a selective spleen tyrosine kinase inhibitor, in chronic lymphocytic leukemia
- (2015) J. Sharman et al. BLOOD
- Elevated expression of HSP90 and the antitumor effect of an HSP90 inhibitor via inactivation of the Akt/mTOR pathway in undifferentiated pleomorphic sarcoma
- (2015) Hirofumi Bekki et al. BMC CANCER
- Hyperphosphorylation of ribosomal protein S6 predicts unfavorable clinical survival in non-small cell lung cancer
- (2015) Bojiang Chen et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- CBL controls a tyrosine kinase network involving AXL, SYK and LYN in nilotinib-resistant chronic myeloid leukaemia
- (2015) Romain Gioia et al. JOURNAL OF PATHOLOGY
- Epstein-Barr virus positive diffuse large B-cell lymphoma predict poor outcome, regardless of the age
- (2015) Ting-Xun Lu et al. Scientific Reports
- A Computational Study of the Effects of Syk Activity on B Cell Receptor Signaling Dynamics
- (2015) Reginald McGee et al. Processes
- Phosphorylation of ribosomal protein S6 confers PARP inhibitor resistance in BRCA1-deficient cancers
- (2015) Chong-kui Sun et al. Oncotarget
- Syk-Induced Phosphatidylinositol-3-Kinase Activation in Epstein-Barr Virus Posttransplant Lymphoproliferative Disorder
- (2013) O. Hatton et al. AMERICAN JOURNAL OF TRANSPLANTATION
- Plasma Epstein-Barr virus DNA predicts outcome in advanced Hodgkin lymphoma: correlative analysis from a large North American cooperative group trial
- (2013) J. A. Kanakry et al. BLOOD
- Epstein-Barr virus latent membrane protein 2A enhances MYC-driven cell cycle progression in a mouse model of B lymphoma
- (2013) K. Fish et al. BLOOD
- EBV-Related Lymphomas: New Approaches to Treatment
- (2013) Jennifer A. Kanakry et al. CURRENT TREATMENT OPTIONS IN ONCOLOGY
- Sustained Complete Responses in Patients With Lymphoma Receiving Autologous Cytotoxic T Lymphocytes Targeting Epstein-Barr Virus Latent Membrane Proteins
- (2013) Catherine M. Bollard et al. JOURNAL OF CLINICAL ONCOLOGY
- Dasatinib therapy results in decreased B cell proliferation, splenomegaly, and tumor growth in a murine model of lymphoma expressing Myc and Epstein-Barr virus LMP2A
- (2012) Jamie L. Dargart et al. ANTIVIRAL RESEARCH
- Epstein-Barr virus LMP2A signaling in statu nascendi mimics a B cell antigen receptor-like activation signal
- (2012) Niklas Engels et al. Cell Communication and Signaling
- Epstein-Barr Virus Latent Membrane Protein-2A Induces ITAM/Syk- and Akt-Dependent Epithelial Migration through V-Integrin Membrane Translocation
- (2012) J. A. Fotheringham et al. JOURNAL OF VIROLOGY
- Epstein–Barr virus latent membrane protein-1 protects B-cell lymphoma from rituximab-induced apoptosis through miR-155-mediated Akt activation and up-regulation of Mcl-1
- (2012) Joo Hyun Kim et al. LEUKEMIA & LYMPHOMA
- Immunotherapy for EBV-associated malignancies
- (2011) Anna Merlo et al. INTERNATIONAL JOURNAL OF HEMATOLOGY
- Sequential treatment with rituximab followed by CHOP chemotherapy in adult B-cell post-transplant lymphoproliferative disorder (PTLD): the prospective international multicentre phase 2 PTLD-1 trial
- (2011) Ralf Trappe et al. LANCET ONCOLOGY
- Involvement of the Syk–mTOR pathway in follicular lymphoma cell invasion and angiogenesis
- (2011) S Fruchon et al. LEUKEMIA
- Rapamycin Reverses Splenomegaly and Inhibits Tumor Development in a Transgenic Model of Epstein-Barr Virus-Related Burkitt's Lymphoma
- (2011) O. Cen et al. MOLECULAR CANCER THERAPEUTICS
- Emerging immunotherapies targeting CD30 in Hodgkin's lymphoma
- (2010) Hans-Peter Gerber BIOCHEMICAL PHARMACOLOGY
- Anomalous constitutive Src kinase activity promotes B lymphoma survival and growth
- (2010) Jiyuan Ke et al. Molecular Cancer
- Epstein-Barr virus-associated lymphoproliferative disease in non-immunocompromised hosts: a status report and summary of an international meeting, 8-9 September 2008
- (2009) J. I. Cohen et al. ANNALS OF ONCOLOGY
- Syk and pTyr'd: Signaling through the B cell antigen receptor
- (2009) Robert L. Geahlen BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH
- Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia
- (2009) J. W. Friedberg et al. BLOOD
- Expression of EBV Latent Antigens, Mammalian Target of Rapamycin, and Tumor Suppression Genes in EBV-Positive Smooth Muscle Tumors: Clinical and Therapeutic Implications
- (2009) K. W. Ong et al. CLINICAL CANCER RESEARCH
- Epstein–Barr virus LMP2A accelerates MYC-induced lymphomagenesis
- (2009) R Bultema et al. ONCOGENE
- Epstein-Barr virus LMP2A bypasses p53 inactivation in a MYC model of lymphomagenesis
- (2009) K. T. Bieging et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Immunotherapy targeting EBV-expressing lymphoproliferative diseases
- (2008) Catherine M. Bollard et al. BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY
- EBV LMP2A provides a surrogate pre-B cell receptor signal through constitutive activation of the ERK/MAPK pathway
- (2008) L. J. Anderson et al. JOURNAL OF GENERAL VIROLOGY
- Current understanding of the role of Epstein–Barr virus in lymphomagenesis and therapeutic approaches to EBV-associated lymphomas
- (2008) Jeffrey I. Cohen et al. LEUKEMIA & LYMPHOMA
- The c-Cbl proto-oncoprotein downregulates EBV LMP2A signaling
- (2008) Masato Ikeda et al. VIROLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More